Thyroid Cancer News and Research

Latest Thyroid Cancer News and Research

Louise A. Villejo recognized with 2010 Julie and Ben Rogers Award for Excellence in Education

Louise A. Villejo, executive director of the Patient Education Office at The University of Texas MD Anderson Cancer Center, is the recipient of the 2010 Julie and Ben Rogers Award for Excellence in Education.

7 Oct 2010

American Cancer Society awards 94 national research, training grants to 70 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 national research and training grants totaling $46,633,000 to 70 institutions nationwide in the first of two grants cycles for 2011.

7 Oct 2010

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.

23 Sep 2010

Lixisenatide experimental diabetes drug shows potential in trial

Researchers at the R&D section of drug maker Sanofi Aventis have confirmed this Monday that a study of its experimental diabetes drug showed better blood sugar control than placebo.

21 Sep 2010

Pazopanib drug reduces thyroid cancer progression: Study

The drug pazopanib may help revolutionize the care of patients with metastatic, rapidly progressive differentiated thyroid cancers, say researchers at Mayo Clinic who are publishing findings of a phase II clinical trial in The Lancet Oncology.

18 Sep 2010

Veracyte presents FNA clinical trial data at International Thyroid Congress

Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, announced that initial data from its large-scale, prospective, multi-center clinical trial were presented today at the 14th International Thyroid Congress, held in Paris, France.

16 Sep 2010

Childhood cancer survivors 5 times more likely to get cancer again: Study

According to a new study, children who survive cancer are at a higher risk of cancer later in life or may die early of other cause. The study included almost 900 young cancer survivors treated at Sydney Children's Hospital, from 1972 to 1999, alongside new cancer cases and early deaths. The risk of cancer was five times higher in childhood cancer survivors, the results showed, compared with the overall NSW population, that these survivors were seven and a half times more likely to die early.

5 Sep 2010

Study shows molecular imaging benefits treatment planning for wide spectrum of cancers

A series of studies published in the September Journal of Nuclear Medicine (JNM) show that molecular imaging plays a critical role in the evaluation and treatment planning for a broad spectrum of cancers, including thyroid cancer and lymphoma.

3 Sep 2010

Mayo researchers develop new laboratory cell lines to study anaplastic thyroid cancer

To their deep dismay, researchers at Mayo Clinic discovered several years ago that laboratory samples of anaplastic thyroid cancer (ATC) they were using to help them find new treatments for this lethal disease were probably some other kind of cancer. It quickly became evident that the situation in their lab was common throughout the world. Up to half of the cell lines that were supposed to originate from patients with this rare thyroid cancer were either colon or melanoma cancer.

25 Aug 2010

Pisgah Labs receives Notice of Allowance for new patent relating to thyroid hormone drugs

Today, Pisgah Labs, Inc. received a Notice of Allowance from the United States Patent and Trademark office for an important new technology patent addressing global stability problems of thyroid hormone drugs.

17 Aug 2010

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and six months ended June 30, 2010, and presented an update on recent clinical and corporate progress.

13 Aug 2010

UCI first medical center on West Coast to perform robotic thyroidectomies

UC Irvine Healthcare is the first medical center on the West Coast and the only one in California to perform robotic thyroidectomies, a procedure that removes the diseased gland without leaving a visible scar on the neck. Dr. Jason Kim, associate clinical professor of otolaryngology and a head and neck cancer specialist, has performed robotic-assisted surgery using the daVinci Surgical System on three patients with thyroid tumors.

16 Jul 2010

UB study: Vietnam veterans exposed to Agent Orange are more likely to develop Graves' disease

Vietnam War-era veterans exposed to Agent Orange appear to have significantly more Graves' disease, a thyroid disorder, than veterans with no exposure, a new study by endocrinologists at the University at Buffalo has shown.

29 Jun 2010

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Late-breaking Novo Nordisk extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes Association showed that once-daily Victoza in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose than Januvia plus metformin at 52 weeks.

28 Jun 2010

Exelixis announces regaining of rights to develop and commercialize XL184

Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.

21 Jun 2010

OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).

16 Jun 2010

ATA members raise concern about reduction in dietary iodine intake

Following publication of an article in the February 18 issue of the New England Journal of Medicine (Vol. 362 No. 7 pp 590-599) by Bibbins-Domingo, et al. that projected the effect of moderate dietary salt reductions on future cardiac disease rates, several members of the American Thyroid Association, concerned about the subsequent potential reduction in availability of iodine, have responded with a letter in the current issue of the NEJM (Vol. 362 No. 23 pp 2224-2226).

15 Jun 2010

Veracyte announces completion of Series B round

Veracyte, Inc. announced today the successful completion of its Series B round, a key milestone toward the company's first product launch later this year. The South San Francisco biotechnology company is committed to pioneering molecular cytology diagnostics to improve patient care and lower health care costs. This round was led by Domain Associates with significant participation from Veracyte's founding investors including Kleiner Perkins Caufield & Byers (KPCB), TPG Biotech (TPG), and Versant Ventures.

10 Jun 2010

Vandetanib extends Progression Free Survival in ZETA phase III study for advanced medullary thyroid cancer

Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo.

8 Jun 2010

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.

7 Jun 2010

Thyroid Cancer News and Research

Latest Thyroid Cancer News and Research

Louise A. Villejo recognized with 2010 Julie and Ben Rogers Award for Excellence in Education

American Cancer Society awards 94 national research, training grants to 70 institutions nationwide

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

Lixisenatide experimental diabetes drug shows potential in trial

Pazopanib drug reduces thyroid cancer progression: Study

Veracyte presents FNA clinical trial data at International Thyroid Congress

Childhood cancer survivors 5 times more likely to get cancer again: Study

Study shows molecular imaging benefits treatment planning for wide spectrum of cancers

Mayo researchers develop new laboratory cell lines to study anaplastic thyroid cancer

Pisgah Labs receives Notice of Allowance for new patent relating to thyroid hormone drugs

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

UCI first medical center on West Coast to perform robotic thyroidectomies

UB study: Vietnam veterans exposed to Agent Orange are more likely to develop Graves' disease

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Exelixis announces regaining of rights to develop and commercialize XL184

OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC

ATA members raise concern about reduction in dietary iodine intake

Veracyte announces completion of Series B round

Vandetanib extends Progression Free Survival in ZETA phase III study for advanced medullary thyroid cancer

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Thyroid Cancer News and Research

Latest Thyroid Cancer News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in